<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.116408</article-id><article-id pub-id-type="publisher-id">ACM-43438</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210600000_13296700.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  过继性细胞免疫疗法在血液系统恶性肿瘤中的研究进展
  Research Progress of Adoptive Cellular Immunotherapy in Hematological Malignancies
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>瑞雪</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>晶月</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姜</surname><given-names>子怡</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>华北理工大学临床医学院，河北 唐山</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>06</month><year>2021</year></pub-date><volume>11</volume><issue>06</issue><fpage>2811</fpage><lpage>2818</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  细胞疗法用于癌症治疗的前景日益广阔，在血液系统恶性肿瘤中的应用也越来越广泛。过继性细胞免疫疗法是指从患者或其他捐赠者那里收集免疫细胞，然后对其进行体外扩增，再输回病人体内杀伤癌细胞的治疗手段。在这篇综述中，我们将重点关注以T淋巴细胞、树突状细胞和自然杀伤细胞为基础的过继性细胞免疫疗法，讨论这些方法在临床上的实际应用，从而更好地为临床医生的临床决策提供参考。
   Cell therapy has an increasingly broad prospect as a cancer treatment, and its application in hematological malignancies is also becoming more and more extensive. Adoptive cellular immunotherapy is a treatment that collects immune cells from patients or other donors, expands them in vitro, and then sends them back into the patient’s body in order to kill cancer cells. In this review, we will focus on adoptive cellular immunotherapy based on T cells, dendritic cells and natural killer cells, discuss the practical applications of these methods in clinical practices, and provide insights for clinicians.
 
</p></abstract><kwd-group><kwd>过继性细胞免疫疗法，血液系统恶性肿瘤，研究进展, Adoptive Cellular Immunotherapy</kwd><kwd> Hematological Malignancy</kwd><kwd> Research Progress</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>细胞疗法用于癌症治疗的前景日益广阔，在血液系统恶性肿瘤中的应用也越来越广泛。过继性细胞免疫疗法是指从患者或其他捐赠者那里收集免疫细胞，然后对其进行体外扩增，再输回病人体内杀伤癌细胞的治疗手段。在这篇综述中，我们将重点关注以T淋巴细胞、树突状细胞和自然杀伤细胞为基础的过继性细胞免疫疗法，讨论这些方法在临床上的实际应用，从而更好地为临床医生的临床决策提供参考。</p></sec><sec id="s2"><title>关键词</title><p>过继性细胞免疫疗法，血液系统恶性肿瘤，研究进展</p></sec><sec id="s3"><title>Research Progress of Adoptive Cellular Immunotherapy in Hematological Malignancies<sup> </sup></title><p>Ruixue Ma, Jingyue Yang, Ziyi Jiang</p><p>School of Clinical Medicine, North China University of Science and Technology, Tangshan Hebei</p><p><img src="//html.hanspub.org/file/50-1572308x4_hanspub.png" /></p><p>Received: May 21<sup>st</sup>, 2021; accepted: Jun. 9<sup>th</sup>, 2021; published: Jun. 25<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/50-1572308x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Cell therapy has an increasingly broad prospect as a cancer treatment, and its application in hematological malignancies is also becoming more and more extensive. Adoptive cellular immunotherapy is a treatment that collects immune cells from patients or other donors, expands them in vitro, and then sends them back into the patient’s body in order to kill cancer cells. In this review, we will focus on adoptive cellular immunotherapy based on T cells, dendritic cells and natural killer cells, discuss the practical applications of these methods in clinical practices, and provide insights for clinicians.</p><p>Keywords:Adoptive Cellular Immunotherapy, Hematological Malignancy, Research Progress</p><disp-formula id="hanspub.43438-formula49"><graphic xlink:href="//html.hanspub.org/file/50-1572308x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/50-1572308x7_hanspub.png" /> <img src="//html.hanspub.org/file/50-1572308x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>据2020年美国癌症协会(ACS)发布的癌症数据统计 [<xref ref-type="bibr" rid="hanspub.43438-ref1">1</xref>]，2020年血液系统恶性肿瘤患者的死亡人数在全球常见癌症中排名位居第十名，同时在中国常见恶性肿瘤的统计数据排名中位居第九名。随着诊疗技术的进步和发展，治疗恶性血液病的方法也从起初的传统治疗方法向目前的免疫靶向疗法方向发展，这些对血液肿瘤的创新治疗技术和新方案应用的发展，使得疾病从根本上治愈成为可能。其中要数过继性细胞免疫疗法(Adoptive Cellular Immunotherapy, ACI)的应用发展最为迅速。据纽约癌症研究所的统计 [<xref ref-type="bibr" rid="hanspub.43438-ref1">1</xref>]，到2019年5月为止，全球癌症研究共有ACI 895项，其中美国有439项，中国有286项。ACI主要是指从患者或其他捐赠者那里收集免疫细胞，然后对其进行体外手术和/或扩增，再通过灌注方式送入病人或患者体内，从而通过直接靶向癌细胞来有效克服癌症细胞的免疫逃逸 [<xref ref-type="bibr" rid="hanspub.43438-ref2">2</xref>]。迄今为止，属于研究热点的ACI主要包括：基因工程技术修饰改造的T细胞、肿瘤浸润淋巴细胞(TIL)、树突状细胞联合细胞因子诱导的杀伤细胞(DC-CIK)、和自然杀伤细胞(NK)等 [<xref ref-type="bibr" rid="hanspub.43438-ref3">3</xref>]。本综述就目前比较热门的ACI进行研究现状和临床应用的归纳总结，以便为临床医生提供关于这一革命性的新治疗方法的实时信息，为其临床治疗决策提供参考。</p></sec><sec id="s6"><title>2. 基因工程技术修饰改造的T细胞免疫疗法</title><sec id="s6_1"><title>2.1. CAR-T细胞免疫疗法</title><p>嵌合抗原受体T细胞免疫疗法(Chimeric Antigen Receptor T-Cell Immunotherapy, CAR-T)目的是解决回输给患者的T细胞无法靶向杀死癌细胞的问题，这一疗法是由G Gross [<xref ref-type="bibr" rid="hanspub.43438-ref4">4</xref>] 等首先提出的。因此第一代CAR-T细胞便随之诞生，准确地杀死肿瘤细胞已经不再是一种奢望。嵌合抗原受体(Chimeric Antigen Receptors, CARs)是一种新型的合成受体，可使T细胞不依赖主要组织相容性复合物(MHC)分子，(也称为人类白细胞抗原，HLA)，而是使用特定抗体片段与位于癌细胞表面的特定抗原进行结合，因此本方法可以应用于所有HLA类型的患者 [<xref ref-type="bibr" rid="hanspub.43438-ref5">5</xref>]。即CAR-T免疫疗法是通过基因工程技术修饰改造而获得的一种新型抗原特异性的过继性细胞免疫疗法，它可以靶向清除患者的癌细胞，以期达到最终痊愈的目标。</p><p>特异性表达肿瘤CARs的T细胞在治疗恶性血液病方面取得了显著的成功，为过继性细胞治疗领域注入了新的活力。到目前为止，CAR-T在非霍奇金淋巴瘤(NHL)，急性淋巴细胞白血病(ALL)和慢性淋巴细胞白血病(CLL)等的治疗中均取得了良好的效果 [<xref ref-type="bibr" rid="hanspub.43438-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.43438-ref7">7</xref>]。同时在其他恶性血液病的治疗中也取得了重大进展，包括急性髓系白血病(AML)、多发性骨髓瘤(MM)和骨髓增生异常综合征(MDS)等 [<xref ref-type="bibr" rid="hanspub.43438-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.43438-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.43438-ref10">10</xref>]。</p><p>迄今为止，两种被用来治愈人体恶性血液病的CAR-T疗法，已获得了美国食品药品监督管理局(FDA)的三项审批通过 [<xref ref-type="bibr" rid="hanspub.43438-ref11">11</xref>]。使用抗CD19 CAR-T细胞治疗的复发/难治性淋巴瘤和白血病患者的完全缓解率(CR)达到前所未有的水平，并且成为FDA审核并批准的第一个基于遗传学和基因改良细胞的治疗方案。Brudno JN [<xref ref-type="bibr" rid="hanspub.43438-ref12">12</xref>] 等首次应用表达新型抗CD19-CAR-Hu19-CD828Z的T细胞去治疗20例B细胞淋巴瘤的患者，研究结果发现接受了Hu19-CD828ZT细胞治疗的患者中有55%能够达到CR，其中只有5%出现了严重的症状，这表明第三代CD19-CAR-T细胞在NHL的治疗中已取得重大的进展。目前，一种人源化抗CD19单链抗体CAR-T细胞被开发出来，并将这些细胞输注到10例复发/难治性-ALL患者体内，对这些患者进行长期随访，所有患者反应均达到CR；其中6例CR超过了18个月，不需要再进一步治疗，4例肿瘤负担高、疾病进展迅速的患者经历了3~4级细胞因子释放综合征和神经毒性 [<xref ref-type="bibr" rid="hanspub.43438-ref13">13</xref>]。现在阻止CAR-T治疗AML的主要障碍就是缺乏与CD19类似的髓样抗原，有研究表明CD33、CD123等AML分化抗原和LeY抗原作为CAR-T作用靶点将会有望治愈AML [<xref ref-type="bibr" rid="hanspub.43438-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.43438-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.43438-ref15">15</xref>]。另外一种新型的抗LILRB4 CAR-T细胞也为治愈AML提供了可能，同时它还能最大限度地降低靶向肿瘤外毒性的风险 [<xref ref-type="bibr" rid="hanspub.43438-ref16">16</xref>]。但目前CAR-T细胞治疗用于临床治疗还存在一些障碍，包括严重的危及生命的毒性、抗肿瘤活性有限和抗原逃逸现象仍然存在等 [<xref ref-type="bibr" rid="hanspub.43438-ref17">17</xref>]。</p></sec><sec id="s6_2"><title>2.2. TCR-T细胞免疫疗法</title><p>虽然T细胞受体改造的T细胞免疫疗法(T cell receptor-engineered T cell Immunotherapy, TCR-T)和CAR-T都是用基因工程技术构建的自体T细胞作为其治疗的基础，但是CAR-T所识别的靶抗原均为细胞表面蛋白，而TCR-T是由肿瘤肽和MHC分子的复合物组成，其治疗原理是识别MHC分子提呈的细胞内抗原片段，所以TCR-T细胞疗法受MHC/HLA的限制 [<xref ref-type="bibr" rid="hanspub.43438-ref18">18</xref>]。S Michael等 [<xref ref-type="bibr" rid="hanspub.43438-ref19">19</xref>] 首次将TCR基因从一个T细胞转移到另一个T细胞，使第二个T细胞具有相同的抗原特异性，这一过程便是TCR疗法的正式起源。目前TCR-T在治疗实体肿瘤方面的研究已经有了显著的进展和成效，比如，NY-ESO-1特异性的TCR-T对于一些患有滑膜细胞肉瘤、黑色素瘤以及肝细胞癌等疾病的患者有很好的疗效 [<xref ref-type="bibr" rid="hanspub.43438-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.43438-ref21">21</xref>]。另外，TCR-T在血液肿瘤中也显示了巨大的潜力。最近的一项系统审查估计，有16%的TCR-T临床试验旨在治疗血液系统恶性肿瘤 [<xref ref-type="bibr" rid="hanspub.43438-ref22">22</xref>]。T Isao [<xref ref-type="bibr" rid="hanspub.43438-ref23">23</xref>] 等在首次在AML和高风险MDS患者中进行了Wilms肿瘤基因产物1 (WT1)特异性的TCR-T人体试验，试验中的8名患者接受了递增剂量的表达WT1TCR构建的自体T细胞的治疗。在研究期结束时，5例患者WT1特异性的TCR-T细胞持续存在，2例患者骨髓白血病细胞百分率短暂下降。这些数据提示，针对HLA-A*02:01或-A*24:02限制性WT1表位的过继转移WT1特异性的TCR-T细胞是安全、耐受性好的，并可能具有体内抗白血病活性。自黑色素瘤中优先表达的抗原(PRAME)首次被确定为T细胞识别的肿瘤抗原以来，对PRAME阳性的血液系统恶性肿瘤患者应用PRAME特异性的TCR-T免疫疗法的研究就在不断进行着。近年来为治疗AML、MDS和MM而开始的PRAME/A*02:01 TCR-T临床试验也在德国进行着 [<xref ref-type="bibr" rid="hanspub.43438-ref24">24</xref>]。G Robson等 [<xref ref-type="bibr" rid="hanspub.43438-ref25">25</xref>]，利用HA-1 TCR转导的T细胞去特异性识别并杀伤原发性白血病细胞，结果显示HA-1 TCR CD8 T细胞可以特异性杀伤HA-1A2 AML、B-ALL和T-ALL和T细胞淋巴瘤细胞系，这些细胞系自然表达或被转导以表达HLA A*0201和HA-1，也就是说HA-1 TCR CD8 T细胞可以有效地瞄准淋巴和骨髓恶性肿瘤。TCR-T疗法已显示出了其治疗潜力，尽管存在一些局限性，比如MHC的匹配和其在细胞表面提呈抗原的必要性、治疗毒性和肿瘤微环境对T细胞的抑制等 [<xref ref-type="bibr" rid="hanspub.43438-ref26">26</xref>]，但是TCR-T疗法仍有很大的研究前景。</p></sec></sec><sec id="s7"><title>3. 其他过继性T细胞免疫疗法</title><sec id="s7_1"><title>3.1. TIL免疫疗法</title><p>肿瘤浸润淋巴细胞(Tumor Infiltrating Lymphocyte, TIL)衍生的T细胞免疫疗法，是指通过内源性TCRs识别肿瘤相关抗原(TAAs)的TIL从切除的肿瘤中分离出来，在IL-2刺激下大规模体外扩增而形成的一种异质性淋巴细胞群 [<xref ref-type="bibr" rid="hanspub.43438-ref27">27</xref>]。因此它保留了对其分离的肿瘤的靶向抗原特异性，然后患者接受此种细胞的回输，便可以靶向清除肿瘤细胞，以大大提高其患者的治疗效果和存活率。在TIL中，大多数细胞是CD3<sup>+</sup>。由于TIL尚未经过基因修饰，并且来自患者的身体，因此不良反应相对较少，这也是TIL治疗的优势 [<xref ref-type="bibr" rid="hanspub.43438-ref28">28</xref>]。随着Rosenberg等 [<xref ref-type="bibr" rid="hanspub.43438-ref29">29</xref>] 将TIL应用于黑色素瘤患者，目前它已经在多种恶性肿瘤中得到应用，其在血液系统恶性肿瘤中同样有效，如淋巴瘤、AL、CL和MM等疾病中均发现TIL具有预后意义，比如免疫抑制性TIL (Treg细胞)的数量则与临床预后较差相关并提示其显著的抗癌作用 [<xref ref-type="bibr" rid="hanspub.43438-ref30">30</xref>]。</p></sec><sec id="s7_2"><title>3.2. CTL免疫疗法</title><p>肿瘤抗原特异细胞毒性T淋巴细胞(Cytotoxic T Cells，CTL)是一类具有特异性杀伤活性的Ｔ细胞群体，患者能产生Ｔ淋巴细胞识别的肿瘤抗原，CTL通过其表面TCR与其结合，诱导CTL释放穿孔素等去直接清除靶细胞 [<xref ref-type="bibr" rid="hanspub.43438-ref31">31</xref>] [<xref ref-type="bibr" rid="hanspub.43438-ref32">32</xref>]。由于它们表达肿瘤限制性抗原，如WT1、PRAME和黑色素瘤相关抗原(MAGE)，因此它们也被证明能成功治疗血液肿瘤 [<xref ref-type="bibr" rid="hanspub.43438-ref33">33</xref>]。另外，当CTL表达Epstein-Barr (EB)病毒相关抗原时，比如LMP1特异性CTL，我们发现它对EBV阳性HL的治疗有显著的效果 [<xref ref-type="bibr" rid="hanspub.43438-ref34">34</xref>]。M Catherine [<xref ref-type="bibr" rid="hanspub.43438-ref35">35</xref>] 等在50名患有HL或NHL患者施用LMP2或LMP1/2特异性的CLT疗法，结果显示，在21名复发/难治性患者中，11人仅接受CTL治疗就进入持续CR，另有2人获得部分缓解(PR)。这说明，这种靶向疗法不仅在消除复发患者的恶性细胞群方面，而且在预防复发和实现持久缓解方面具有一定作用，在疾病早期施用时也不会产生长期毒性。</p></sec></sec><sec id="s8"><title>4. 以DC为基础的免疫疗法</title><sec id="s8_1"><title>4.1. DC免疫疗法</title><p>树突状细胞(Dendritic Cells, DCs)是先天免疫系统和自适应免疫系统之间的重要纽带，是抗原特异性T细胞反应的关键控制器。它是强大的抗原提呈细胞，具有获取和处理抗原以呈递给T细胞的能力，并且可以表达高水平的共刺激或共抑制分子 [<xref ref-type="bibr" rid="hanspub.43438-ref36">36</xref>]。利用DC作为开发癌症疫苗的平台正是基于它的独特效力，即能够诱导初级免疫应答的能力。目前，DC肿瘤疫苗已经在一些血液系统恶性肿瘤的临床试验中进行了探索，包括NHL、CL、MM和AML [<xref ref-type="bibr" rid="hanspub.43438-ref37">37</xref>]。另外，在2015年，Suehiro等 [<xref ref-type="bibr" rid="hanspub.43438-ref38">38</xref>] 人报告了一项针对成人T细胞白血病/淋巴瘤(ATLL)患者的DC肿瘤疫苗的早期临床试验。在这项研究中，用Tax (一种人类T细胞白血病病毒I型(HTLV-1)的肽产物)脉冲自体DC制备DC肿瘤疫苗。在进行治疗的3名患者中有2名在前8周内出现PR，其中1名随后转为CR。这2名患者在接种疫苗后24个月和19个月仍处于缓解状态，无需进一步化疗。DC疫苗的安全性在迄今为止进行的临床试验中已经得到很好的证实。观察到的副作用(包括发烧、注射部位反应、腺病和疲劳)也相对温和且短暂 [<xref ref-type="bibr" rid="hanspub.43438-ref39">39</xref>]。现在面临的挑战是，肿瘤微环境会阻碍DC发挥正常功能，所以我们目前急需解决的问题就是如何减少DCreg和Treg等免疫抑制细胞的作用 [<xref ref-type="bibr" rid="hanspub.43438-ref40">40</xref>]。</p></sec><sec id="s8_2"><title>4.2. DC-CIK免疫疗法</title><p>DC-CIK是指与细胞因子诱导的杀伤细胞(CIK)免疫疗法共同培养的DC，是一种广泛适用的、非MHC依赖的过继性细胞免疫疗法 [<xref ref-type="bibr" rid="hanspub.43438-ref41">41</xref>]。由于CIK细胞具有增殖能力强等特性，两种细胞联合培养，可提高靶向杀伤肿瘤细胞的能力 [<xref ref-type="bibr" rid="hanspub.43438-ref42">42</xref>]，同时可以帮助机体恢复免疫功能，使得抗肿瘤效果更好。该免疫疗法目前已经被用于治疗AL和MM等疾病，并显示出了其出色的抗恶性血液病的能力 [<xref ref-type="bibr" rid="hanspub.43438-ref43">43</xref>]。Yan Bai [<xref ref-type="bibr" rid="hanspub.43438-ref28">28</xref>] 等进行了对化疗后的22名AML儿童应用DC-CIK免疫疗法的临床试验，22例患者的平均随访期为71个月。结果显示，其中2例AML患者复发，DC-CIK治疗后第3个月15例患者外周血CD3(+)/CD8(+)细胞百分比(36.73% &#177; 12.51%)显着高于治疗前(29.20% &#177; 8.34%, P &lt; 0.05)，治疗前5例患者的MRD率 &gt; 0.1%，治疗后3个月MRD率 &lt; 0.1%。在输注DC-CIK的过程中，22例中有7例患者出现了包括发烧、发冷和荨麻疹在内的副作用，但在对症治疗后迅速消失了。说明可以通过DC-CIK治疗消除AML儿童的MRD，并且安全且副作用较小。另外将DC-CIK联合其它免疫细胞来治疗恶性血液病的临床试验也在不断进行中 [<xref ref-type="bibr" rid="hanspub.43438-ref44">44</xref>]。</p></sec></sec><sec id="s9"><title>5. 以NK为基础的免疫疗法</title><sec id="s9_1"><title>5.1. NK免疫疗法</title><p>NK细胞是免疫系统的组成部分，是癌症免疫治疗中重要的效应细胞。NK细胞缺少TCR，不会引起移植物抗宿主反应 [<xref ref-type="bibr" rid="hanspub.43438-ref45">45</xref>]。同时，NK细胞的来源也是广泛的，我们可从外周血、脐血和诱导多能干细胞等途径获取大量NK细胞 [<xref ref-type="bibr" rid="hanspub.43438-ref46">46</xref>]。肿瘤相关的配体触发可以使NK细胞激活并迅速杀死多个相邻细胞，这种特性在免疫细胞中是独一无二的 [<xref ref-type="bibr" rid="hanspub.43438-ref47">47</xref>]，它的这种天然抗肿瘤活性已成为癌症，特别是血液肿瘤(比如：AML、MM和MDS)的治疗依据之一。NK免疫疗法是治疗AML的新兴方法，Rizwan等 [<xref ref-type="bibr" rid="hanspub.43438-ref48">48</xref>] 利用IL-12、IL-15和IL-18等细胞因子诱导的记忆性NK细胞被短暂激活后分化，有9名AML患者进行了第一阶段的临床试验，观察到5人有临床反应，其中有4名获得CR，这是体内抗白血病活动的初步证据。因此，使用IL-12、IL-15和IL-18预激活NK细胞，从而产生类似的记忆性NK细胞，是一种治疗AML很有希望的方法。Nina等 [<xref ref-type="bibr" rid="hanspub.43438-ref49">49</xref>] 为接受大剂量化疗和自体造血干细胞移植的12名MM患者进行了脐带血衍生(CB) NK细胞的首次人类研究，其中10名患者获得了PR，8名接近CR，6例患者体内检测到CB-NK细胞其表型为活化型(NKG2D/NKP30)，这些数据证明了这种新型细胞疗法的进一步发展。Andreas [<xref ref-type="bibr" rid="hanspub.43438-ref50">50</xref>] 等描述了第一阶段/第二阶段采用IL-2激活的单体NK细胞，用于16名复发/难治性MDS患者。16名患者中6名表现为CR、骨髓CR或PR。此外，3名患者达到无白血病状态或疾病稳定，总体而言这项研究表明，高风险MDS对NK细胞治疗有反应。</p></sec><sec id="s9_2"><title>5.2. CAR-NK免疫疗法</title><p>CAR-T细胞的研究结果为探索自然杀伤(NK)细胞等其他免疫细胞类型的临床应用提供了新的思路，而这些细胞可能会规避CAR-T细胞的某些局限性 [<xref ref-type="bibr" rid="hanspub.43438-ref45">45</xref>]。由于NK细胞可以进行异种移植，并有可能成为现成产品，所以使CAR-NK免疫疗法也不断发展起来。CAR-NK源自一种新型的基因改造，表现出增强的NK细胞毒性、特异性和针对性 [<xref ref-type="bibr" rid="hanspub.43438-ref51">51</xref>]。这些产品可能比CAR-T免疫治疗更安全 [<xref ref-type="bibr" rid="hanspub.43438-ref52">52</xref>]，因为它们可产生细胞因子，包括IFN-γ和GM-CSF，且毒性比T细胞产生的细胞因子要低 [<xref ref-type="bibr" rid="hanspub.43438-ref53">53</xref>]。CAR修饰的NK细胞一旦识别CD19、CD20、CD138等特异性靶点，就会分泌细胞因子，有效杀伤表达抗原的肿瘤细胞。CAR-NK免疫疗法已经用于血液系统恶性肿瘤，尤其是在B细胞恶性肿瘤中取得了显著成效 [<xref ref-type="bibr" rid="hanspub.43438-ref54">54</xref>]。Enli Liu等 [<xref ref-type="bibr" rid="hanspub.43438-ref55">55</xref>] 给11例复发或难治性CD19阳性NHL或CLL患者施用了来源于脐血的HLA错配的抗CD19CAR-NK细胞，在这些患者中，7例(4例淋巴瘤，3例CLL)获得CR，且没有产生重大毒性反应。Tang等 [<xref ref-type="bibr" rid="hanspub.43438-ref56">56</xref>] 人首次将CD33-CAR-NK92细胞注射到10例复发/难治性AML患者中。治疗后仅有3例患者出现轻度发热和CRS，次日恢复正常，这表明CAR NK-92疗法可能为治疗AML和其他癌症提供安全、经济、现成的产品。</p></sec></sec><sec id="s10"><title>6. 结语</title><p>肿瘤过继细胞免疫治疗领域是一个相对较新且发展迅速的研究领域。尽管基于T细胞、DC细胞和NK细胞的过继性细胞免疫疗法的临床研究获得了大量令人鼓舞的新数据，但细胞治疗领域仍有很大的发展空间。如何将这些细胞工业化生产，以及如何为不同肿瘤选择合理的免疫细胞进行治疗，都是有待我们去解决的问题。总之，基于免疫系统能够达到诱导长期和持久的免疫反应从而杀伤肿瘤细胞的特点，过继性细胞免疫疗法可以为血液系统肿瘤的治疗提供更有效的方案，值得进一步的研究探讨。</p></sec><sec id="s11"><title>文章引用</title><p>马瑞雪,杨晶月,姜子怡. 过继性细胞免疫疗法在血液系统恶性肿瘤中的研究进展Research Progress of Adoptive Cellular Immunotherapy in Hematological Malignancies[J]. 临床医学进展, 2021, 11(06): 2811-2818. https://doi.org/10.12677/ACM.2021.116408</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43438-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Sung, H., Siegel, R.L., Laversanne, M., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.  
&lt;br&gt;https://doi.org/10.3322/caac.21660</mixed-citation></ref><ref id="hanspub.43438-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Restifo, N.P., Dudley, M.E. and Rosenberg, S.A. (2012) Adoptive Immunotherapy for Cancer: Harnessing the T Cell Response. Nature Reviews Immunology, 12, 269-281. &lt;br&gt;https://doi.org/10.1038/nri3191</mixed-citation></ref><ref id="hanspub.43438-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">潘玉竹, 曹政. 肿瘤过继性细胞治疗的研究进展[J]. 免疫学杂志, 2020, 36(1): 86-92.</mixed-citation></ref><ref id="hanspub.43438-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Gross, G., Waks, T. and Eshhar, Z. (1989) Expression of Immunoglobulin-T-Cell Receptor Chimeric Molecules as Functional Receptors with Antibody-Type Specificity. Proceedings of National Academy of Sciences of the United States of America, 86, 10024-10028. &lt;br&gt;https://doi.org/10.1073/pnas.86.24.10024</mixed-citation></ref><ref id="hanspub.43438-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Hong, M., Clubb, J.D. and Chen, Y.Y. (2020) Engineering CAR-T Cells for Next-Generation Cancer Therapy. Cancer Cell, 38, 473-488. &lt;br&gt;https://doi.org/10.1016/j.ccell.2020.07.005</mixed-citation></ref><ref id="hanspub.43438-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Holstein, S.A. and Lunning, M.A. (2020) CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress. Clinical Pharmacology &amp; Therapeutics, 107, 112-122. &lt;br&gt;https://doi.org/10.1002/cpt.1674</mixed-citation></ref><ref id="hanspub.43438-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Fraietta, J.A., Lacey, S.F., Orlando, E.J., et al. (2018) Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy of Chronic Lymphocytic Leukemia. Nature Medicine, 24, 563-571.  
&lt;br&gt;https://doi.org/10.1038/s41591-018-0010-1</mixed-citation></ref><ref id="hanspub.43438-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Hofmann, S., Schubert, M.-L., Wang, L., et al. (2019) Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML). Journal of Clinical Medicine, 8, 200. &lt;br&gt;https://doi.org/10.3390/jcm8020200</mixed-citation></ref><ref id="hanspub.43438-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Gagelmann, N., Riecken, K., Wolschke, C., et al. (2020) Development of CAR-T Cell Therapies for Multiple Myeloma. Leukemia, 34, 2317-2332. &lt;br&gt;https://doi.org/10.1038/s41375-020-0930-x</mixed-citation></ref><ref id="hanspub.43438-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Mikkilineni, L. and Kochenderfer, J.N. (2021) CAR T Cell Therapies for Patients with Multiple Myeloma. Nature Reviews Clinical Oncology, 18, 71-84. &lt;br&gt;https://doi.org/10.1038/s41571-020-0427-6</mixed-citation></ref><ref id="hanspub.43438-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Sengupta, R. and Honey, K. (2020) AACR Cancer Progress Report 2020: Turning Science into Lifesaving Care. Clinical Cancer Research, 26, 5055. &lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-20-3187</mixed-citation></ref><ref id="hanspub.43438-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Brudno, J.N., Lam, N., Vanasse, D., et al. (2020) Safety and Feasibility of Anti-CD19 CAR T Cells with Fully Human Binding Domains in Patients with B-Cell Lymphoma. Nature Medicine, 26, 270-280.  
&lt;br&gt;https://doi.org/10.1038/s41591-019-0737-3</mixed-citation></ref><ref id="hanspub.43438-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Heng, G., Jia, J., Li, S., et al. (2020) Sustained Therapeutic Efficacy of Humanized Anti-CD19 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Acute Lymphoblastic Leukemia. Clinical Cancer Research, 26, 1606-1615.  
&lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-19-1339</mixed-citation></ref><ref id="hanspub.43438-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Z.Z., et al. (2020) Construction of a New Anti-CD123 Chimeric Antigen Receptor T Cells and Effect of Anti-Acute Myeloid Leukemia. Zhonghua Xue Ye Xue Za Zhi, 41, 192-197.</mixed-citation></ref><ref id="hanspub.43438-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Ritchie, D.S., Neeson, P.J., Khot, A., et al. (2013) Persistence and Efficacy of Second Generation CAR T Cell against the LeY Antigen in Acute Myeloid Leukemia. Molecular Therapy, 21, 2122-2129. &lt;br&gt;https://doi.org/10.1038/mt.2013.154</mixed-citation></ref><ref id="hanspub.43438-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">John, S., Chen, H., Deng, M., et al. (2018) A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML. Molecular Therapy, 26, 2487-2495. &lt;br&gt;https://doi.org/10.1016/j.ymthe.2018.08.001</mixed-citation></ref><ref id="hanspub.43438-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Sterner, R.C. and Sterner, R.M. (2021) CAR-T Cell Therapy: Current Limitations and Potential Strategies. Blood Cancer Journal, 11, Article No. 69. &lt;br&gt;https://doi.org/10.1038/s41408-021-00459-7</mixed-citation></ref><ref id="hanspub.43438-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, L. and Cao, Y.J. (2019) Engineered T Cell Therapy for Cancer in the Clinic. Frontiers in Immunology, 10, 2250.  
&lt;br&gt;https://doi.org/10.3389/fimmu.2019.02250</mixed-citation></ref><ref id="hanspub.43438-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Blüthmann, H., Kisielow, P., Uematsu, Y., et al. (1988) T-Cell-Specific Deletion of T-Cell Receptor Transgenes Allows Functional Rearrangement of Endogenous Alpha- and Beta-Genes. Nature, 334, 156-159.  
&lt;br&gt;https://doi.org/10.1038/334156a0</mixed-citation></ref><ref id="hanspub.43438-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Robbins, P.F., Kassim, S.H., Tran, T.L.N., et al. (2015) A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-Cell Receptor: Long-Term Follow-Up and Correlates with Response. Clinical Cancer Research, 21, 1019-1027. &lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-14-2708</mixed-citation></ref><ref id="hanspub.43438-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Galva, L.D.C., Cai, L., Shao, Y., et al. (2020) Engineering T Cells for Immunotherapy of Primary Human Hepatocellular Carcinoma. Journal of Genetics and Genomics, 47, 1-15. &lt;br&gt;https://doi.org/10.1016/j.jgg.2020.01.002</mixed-citation></ref><ref id="hanspub.43438-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, J. and Wang, L. (2019) The Emerging World of TCR-T Cell Trials against Cancer: A Systematic Review. Technology in Cancer Research &amp; Treatment, 18, 1533033819831068. &lt;br&gt;https://doi.org/10.1177/1533033819831068</mixed-citation></ref><ref id="hanspub.43438-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Tawara, I., Kageyama, S., Miyahara, Y., et al. (2017) Safety and Persistence of WT1-Specific T-Cell Receptor Gene-Transduced Lymphocytes in Patients with AML and MDS. Blood, 130, 1985-1994.  
&lt;br&gt;https://doi.org/10.1182/blood-2017-06-791202</mixed-citation></ref><ref id="hanspub.43438-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Biernacki, M.A., Brault, M. and Bleakley, M. (2019) T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies. The Cancer Journal, 25, 179-190. &lt;br&gt;https://doi.org/10.1097/PPO.0000000000000378</mixed-citation></ref><ref id="hanspub.43438-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Dossa, R.G., Cunningham, T., Sommermeyer, D., et al. (2018) Development of T-Cell Immunotherapy for Hematopoietic Stem Cell Transplantation Recipients at Risk of Leukemia Relapse. Blood, 131, 108-120.  
&lt;br&gt;https://doi.org/10.1182/blood-2017-07-791608</mixed-citation></ref><ref id="hanspub.43438-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">叶春梅, 叶韵斌. 实体肿瘤TCR-T治疗研究的现状与面临的挑战[J]. 中国肿瘤生物治疗杂志, 2020, 27(9): 959-967.</mixed-citation></ref><ref id="hanspub.43438-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Rohaan, M.W., van den Berg, J.H., Kvistborg, P., et al. (2018) Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Melanoma: A Viable Treatment Option. Journal for ImmunoTherapy of Cancer, 6, 102.  
&lt;br&gt;https://doi.org/10.1186/s40425-018-0391-1</mixed-citation></ref><ref id="hanspub.43438-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Bai, Y., Zheng, J., Wang, N., et al. (2015) Effects of Dendritic Cell-Activated and Cytokine-Induced Killer Cell Therapy on 22 Children with Acute Myeloid Leukemia after Chemotherapy. Journal of Huazhong University of Science and Technology [Medical Sciences], 35, 689-693. &lt;br&gt;https://doi.org/10.1007/s11596-015-1491-5</mixed-citation></ref><ref id="hanspub.43438-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Rosenberg, S.A., Packard, B.S., Aebersold, P.M., et al. (1988) Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma. A Preliminary Report. The New England Journal of Medicine, 319, 1676-1680. &lt;br&gt;https://doi.org/10.1056/NEJM198812223192527</mixed-citation></ref><ref id="hanspub.43438-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">梁铭, 张辉, 陈福雄. 肿瘤浸润性淋巴细胞在血液肿瘤中作用的临床研究进展[J]. 中国实验血液学杂志, 2016, 24(4): 1241-1247.</mixed-citation></ref><ref id="hanspub.43438-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Coulie, P.G., Van den Eynde, B.J., van der Bruggen, P. and Boon, T. (2014) Tumour Antigens Recognized by T Lymphocytes: At the Core of Cancer Immunotherapy. Nature Reviews Cancer, 14, 135-146.  
&lt;br&gt;https://doi.org/10.1038/nrc3670</mixed-citation></ref><ref id="hanspub.43438-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Chiou, S.-H., Sheu, B.-C., Chang, W.-C., et al. (2005) Current Concepts of Tumor-Infiltrating Lymphocytes in Human Malignancies. Journal of Reproductive Immunology, 67, 35-50. &lt;br&gt;https://doi.org/10.1016/j.jri.2005.06.002</mixed-citation></ref><ref id="hanspub.43438-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Leon, E., Ranganathan, R. and Savoldo, B. (2020) Adoptive T Cell Therapy: Boosting the Immune System to Fight Cancer. Seminars in Immunology, 49, 101437. &lt;br&gt;https://doi.org/10.1016/j.smim.2020.101437</mixed-citation></ref><ref id="hanspub.43438-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Gottschalk, S., Edwards, O.L., Sili, U., et al. (2003) Generating CTLs against the Subdominant Epstein-Barr Virus LMP1 Antigen for the Adoptive Immunotherapy of EBV-Associated Malignancies. Blood, 101, 1905-1912.  
&lt;br&gt;https://doi.org/10.1182/blood-2002-05-1514</mixed-citation></ref><ref id="hanspub.43438-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Bollard, C.M., Gottschalk, S., Torrano, V., et al. (2014) Sustained Complete Responses in Patients with Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins. Journal of Clinical Oncology, 32, 798-808. &lt;br&gt;https://doi.org/10.1200/JCO.2013.51.5304</mixed-citation></ref><ref id="hanspub.43438-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Steinman, R.M. (2012) Decisions about Dendritic Cells: Past, Present, and Future. Annual Review of Immunology, 30, 1-22. &lt;br&gt;https://doi.org/10.1146/annurev-immunol-100311-102839</mixed-citation></ref><ref id="hanspub.43438-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Weinstock, M., Rosenblatt, J. and Avigan, D. (2017) Dendritic Cell Therapies for Hematologic Malignancies. Molecular Therapy—Methods &amp; Clinical Development, 5, 66-75. &lt;br&gt;https://doi.org/10.1016/j.omtm.2017.03.004</mixed-citation></ref><ref id="hanspub.43438-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Suehiro, Y., Hasegawa, A., Iino, T., et al. (2015) Clinical Outcomes of a Novel Therapeutic Vaccine with Tax Peptide-Pulsed Dendritic Cells for Adult T Cell Leukaemia/Lymphoma in a Pilot Study. British Journal of Haematology, 169, 356-367. &lt;br&gt;https://doi.org/10.1111/bjh.13302</mixed-citation></ref><ref id="hanspub.43438-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Sabado, R.L., Balan, S. and Bhardwaj, N. (2017) Dendritic Cell-Based Immunotherapy. Cell Research, 27, 74-95.  
&lt;br&gt;https://doi.org/10.1038/cr.2016.157</mixed-citation></ref><ref id="hanspub.43438-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">王建莉, 路小超, 封贺, 赵同军. 树突状细胞与肿瘤免疫系统相互作用研究进展[J]. 生命科学, 2020, 32(2): 188-194.</mixed-citation></ref><ref id="hanspub.43438-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Wang, S., Wang, X., Zhou, X., et al. (2020) DC-CIK as a Widely Applicable Cancer Immunotherapy. Expert Opinion on Biological Therapy, 20, 601-607. &lt;br&gt;https://doi.org/10.1080/14712598.2020.1728250</mixed-citation></ref><ref id="hanspub.43438-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Mosińska, P., Gabryelska, A., Zasada, M., et al. (2017) Dual Functional Capability of Dendritic Cells—Cytokine-Induced Killer Cells in Improving Side Effects of Colorectal Cancer Therapy. Frontiers in Pharmacology, 8, 126.  
&lt;br&gt;https://doi.org/10.3389/fphar.2017.00126</mixed-citation></ref><ref id="hanspub.43438-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">时靖, 马甜甜, 刘华胜. 树突状细胞联合细胞因子诱导的杀伤细胞免疫治疗血液系统肿瘤的研究进展[J]. 中国实验血液学杂志, 2018, 26(4): 1235-1239.</mixed-citation></ref><ref id="hanspub.43438-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">刘华胜, 时靖, 刘海波, 等. 自体DC-CIK细胞联合其它免疫细胞治疗血液系统肿瘤的回顾性研究[J]. 中国实验血液学杂志, 2019, 27(3): 983-990.</mixed-citation></ref><ref id="hanspub.43438-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Rezvani, K., Rouce, R., Liu, E. and Shpall, E. (2017) Engineering Natural Killer Cells for Cancer Immunotherapy. Molecular Therapy, 25, 1769-1781. &lt;br&gt;https://doi.org/10.1016/j.ymthe.2017.06.012</mixed-citation></ref><ref id="hanspub.43438-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Geiger, T.L. and Sun, J.C. (2016) Development and Maturation of Natural Killer Cells. Current Opinion in Immunology, 39, 82-89. &lt;br&gt;https://doi.org/10.1016/j.coi.2016.01.007</mixed-citation></ref><ref id="hanspub.43438-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Shimasaki, N., Jain, A. and Campana, D. (2020) NK Cells for Cancer Immunotherapy. Nature Reviews Drug Discovery, 19, 200-218. &lt;br&gt;https://doi.org/10.1038/s41573-019-0052-1</mixed-citation></ref><ref id="hanspub.43438-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Romee, R., Rosario, M., Berrien-Elliott, M.M., et al. (2016) Cytokine-Induced Memory-Like Natural Killer Cells Exhibit Enhanced Responses against Myeloid Leukemia. Science Translational Medicine, 8, 357ra123.  
&lt;br&gt;https://doi.org/10.1126/scitranslmed.aaf2341</mixed-citation></ref><ref id="hanspub.43438-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Shah, N., Li, L., McCarty, J., et al. (2017) Phase I Study of Cord Blood-Derived Natural Killer Cells Combined with Autologous Stem Cell Transplantation in Multiple Myeloma. British Journal of Haematology, 177, 457-466.  
&lt;br&gt;https://doi.org/10.1111/bjh.14570</mixed-citation></ref><ref id="hanspub.43438-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Björklund, A.T., Carlsten, M., Sohlberg, E., et al. (2018) Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML. Clinical Cancer Research, 24, 1834-1844.  
&lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-17-3196</mixed-citation></ref><ref id="hanspub.43438-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Fang, F., Xiao, W. and Tian, Z. (2017) NK Cell-Based Immunotherapy for Cancer. Seminars in Immunology, 31, 37-54.  
&lt;br&gt;https://doi.org/10.1016/j.smim.2017.07.009</mixed-citation></ref><ref id="hanspub.43438-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Wang, W., Jiang, J. and Wu, C. (2020) CAR-NK for Tumor Immunotherapy: Clinical Transformation and Future Prospects. Cancer Letters, 472, 175-180. &lt;br&gt;https://doi.org/10.1016/j.canlet.2019.11.033</mixed-citation></ref><ref id="hanspub.43438-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">Klingemann, H. (2014) Are Natural Killer Cells Superior CAR Drivers? Oncoimmunology, 3, e28147.  
&lt;br&gt;https://doi.org/10.4161/onci.28147</mixed-citation></ref><ref id="hanspub.43438-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">Romanski, A., Uherek, C., Bug, G., et al. (2016) CD19-CAR Engineered NK-92 Cells Are Sufficient to Overcome NK Cell Resistance in B-Cell Malignancies. Journal of Cellular and Molecular Medicine, 20, 1287-1294.  
&lt;br&gt;https://doi.org/10.1111/jcmm.12810</mixed-citation></ref><ref id="hanspub.43438-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Liu, E., Marin, D., Banerjee, P., et al. (2020) Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. The New England Journal of Medicine, 382, 545-553. &lt;br&gt;https://doi.org/10.1056/NEJMoa1910607</mixed-citation></ref><ref id="hanspub.43438-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">Tang, X., Yang, L., Li, Z., et al. (2018) First-in-Man Clinical Trial of CAR NK-92 Cells: Safety Test of CD33-CAR NK-92 Cells in Patients with Relapsed and Refractory Acute Myeloid Leukemia. American Journal of Cancer Research, 8, 1083-1089.</mixed-citation></ref></ref-list></back></article>